# OnCo record sx-682 (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/sx-682/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "sx-682" ;
  schema:name "SX-682"@en ;
  schema:description "SX-682 is an experimental tablet from Syntrix Pharmaceuticals that blocks the CXCR1 and CXCR2 receptors on immune-suppressing cells. It is in phase 2 trials, alone or with other medicines, in prostate cancer, lung cancer and other cancers."@en ;
  schema:url <https://onco.cc/drugs/sx-682/> ;
  schema:dateModified "2026-11-04"^^xsd:date ;
  schema:citation <https://syntrixbio.com/pages/immuno-oncology/>, <https://clinicaltrials.gov/search?intr=SX-682> ;
  onco:status "phase-2" ;
  onco:tag "pipeline" ;
  onco:modality "Oral small-molecule inhibitor" ;
  onco:cancers <https://onco.cc/cancers/prostate/>, <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/colon-cancer/>, <https://onco.cc/cancers/rectal-cancer/> ;
  onco:companies <https://onco.cc/companies/syntrix-pharmaceuticals/> ;
  onco:trials <https://onco.cc/trials/nct06228053/>, <https://onco.cc/trials/nct05570825/>, <https://onco.cc/trials/nct07322341/>, <https://onco.cc/trials/nct06149481/> .